Premium
Meta‐analysis reveals no significant correlation between breast cancer survival and ErbB3 expression
Author(s) -
Kim Hyun Jung,
Kim Aeree,
Ahn HyeongSik,
Ahn Il Min,
Choi Jinhyuk,
Chang Hyeyoon
Publication year - 2015
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12371
Subject(s) - breast cancer , erbb3 , meta analysis , oncology , hazard ratio , medicine , confidence interval , immunohistochemistry , multivariate analysis , univariate analysis , subgroup analysis , cancer , epidermal growth factor receptor
Prognostic value of ErbB3 in human breast cancer is still controversial. However, the roles of ErbB3 receptors in drug resistance are recently emerging. The objective of this study was to evaluate the relationship between ErbB3 expression and survival of breast cancer via meta‐analysis. A systematic literature search was conducted and 32 potentially relevant studies were included in the meta‐analysis. Outcomes presented in searched literatures can be classified as disease free survival ( DFS ), overall survival ( OS ), and progress free survival ( PFS ) values. Meta‐analysis was performed for each group. Results showed no statistically significant difference in survival. The overall hazard ratio of PFS , DFS , and OS of ErbB3 expression was 1.40 [95% confidence interval/ CI (0.51, 3.83)], 1.07 [95% CI (0.82, 1.40)], and 1.15 [95% CI (0.91, 1.44)], respectively. Subgroup analysis according to ErbB2 receptor status, ErbB3 assessment methods (immunohistochemistry/ IHC vs non‐ IHC ), and analysis type (multivariate and univariate analysis) were performed. No significant association was found. Using various assessment methods and patient populations, our results revealed that there was no significant correlation between ErbB3 expression and breast cancer survival. Further studies on heterodimers of ErbB3 and other molecular markers involved in ErbB3 related pathway are merited.